Skip Navigation


Journal of the National Cancer Institute Advance Access originally published online on September 11, 2007
JNCI Journal of the National Cancer Institute 2007 99(18):1353; doi:10.1093/jnci/djm173
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
99/18/1353-a    most recent
djm173v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Savage, L.
Right arrow Articles by Widener, A.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Savage, L.
Right arrow Articles by Widener, A.
Related Collections
Right arrowRelated Articles in JNCI
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© Oxford University Press 2007.

MEMO TO THE MEDIA

Press Release

Finasteride Unlikely to Induce High Grade Prostate Cancers

Liz Savage, Andrea Widener

jncimedia@oxfordjournals.org
301-841-1287

The first 10% of the full text of this article appears below.

An increase in high-grade prostate cancer among men taking the drug finasteride is likely caused by an increased detection of cancers, and not by the development of more high-grade cancers, according to two studies published online September 11 in the Journal of the National Cancer Institute.

The Prostate Cancer Prevention Trial (PCPT) was the first long-term randomized trial of a possible drug to prevent prostate cancer. The trial showed a nearly 25 percent reduction in prostate cancer incidence among men who . . . [Full Text of this Article]

Note to Reporters:


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related Articles in JNCI

Finasteride and High-Grade Prostate Cancer in the Prostate Cancer Prevention Trial
M. Scott Lucia, Jonathan I. Epstein, Phyllis J. Goodman, Amy K. Darke, Victor E. Reuter, Francisco Civantos, Catherine M. Tangen, Howard L. Parnes, Scott M. Lippman, Francisco G. La Rosa, Michael W. Kattan, E. David Crawford, Leslie G. Ford, Charles A. Coltman, Jr, and Ian M. Thompson
J Natl Cancer Inst 2007 99: 1375-1383. [Abstract] [Full Text] [PDF]

Detection Bias Due to the Effect of Finasteride on Prostate Volume: A Modeling Approach for Analysis of the Prostate Cancer Prevention Trial
Yael C. Cohen, Kenneth S. Liu, Norman L. Heyden, Alexandra D. Carides, Keaven M. Anderson, Anastasia G. Daifotis, and Peter H. Gann
J Natl Cancer Inst 2007 99: 1366-1374. [Abstract] [Full Text] [PDF]

High-Grade Prostate Cancer in the Prostate Cancer Prevention Trial: Fact or Artifact?
Gerald L. Andriole, Peter A. Humphrey, Robert J. Serfling, and Robert L. Grubb
J Natl Cancer Inst 2007 99: 1355-1356. [Extract] [Full Text] [PDF]